David A. Sinclair A.O., Ph.D.

David A. Sinclair A.O., Ph.D. has had a long and distinguished career in the field of aging research. David A. began their career in 1999 as a Professor at Harvard University. In 2005, they co-founded the Paul F. Glenn Center for Biology of Aging Research, where they served as Co-Director. In 2010, they co-founded CohBar, Inc., where they served as Co-Founder and Scientific Advisor. In 2013, they co-founded Metrobiotech International, where they served as Co-founder, Board Member, Scientific Advisor, and Investor. In 2015, they co-founded Liberty BioSecurity, LLC, where they served as Co-Founder, Chief Scientific Advisor, and Investor. In 2016, they joined Arc Bio as Co-Founder, Board Member, Advisor, and Investor. David A. also joined EdenRoc Sciences that year as a Member of the Board, Advisor, and Investor. In 2017, they joined Life Biosciences as a Board Member, Investor, and Advisor. In 2020, they co-founded Immetas Therapeutics, where they serve as Co-founder and Board Member. Finally, in 2022, they co-founded Tally Health, where they serve as Co-Founder.

David A. Sinclair A.O., Ph.D. began their educational journey at the University of New South Wales (UNSW) in 1987, where they earned a B.S. and Ph.D. in Genetics, Molecular Biology, Biochemistry, and Marine Biology. Following their time at UNSW, they completed Postdoctoral Training in Genetics at the Massachusetts Institute of Technology from 1995 to 1999.